Journal article
Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial
Abstract
BACKGROUND: Panitumumab is a fully human monoclonal antibody that targets EGFR. We aimed to compare chemoradiotherapy plus panitumumab with chemoradiotherapy alone in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck.
METHODS: In this international, open-label, randomised, controlled, phase 2 trial, we recruited patients with locally advanced squamous-cell carcinoma of the head and neck from 41 sites in …
Authors
Mesía R; Henke M; Fortin A; Minn H; Ancona ACY; Cmelak A; Markowitz AB; Hotte SJ; Singh S; Chan ATC
Journal
The Lancet Oncology, Vol. 16, No. 2, pp. 208–220
Publisher
Elsevier
Publication Date
February 2015
DOI
10.1016/s1470-2045(14)71198-2
ISSN
1470-2045
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdolescentAdultAgedAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapyCisplatinDose Fractionation, RadiationFemaleFollow-Up StudiesHead and Neck NeoplasmsHumansInternational AgenciesMaleMiddle AgedNeoplasm StagingNeoplasms, Squamous CellPanitumumabPrognosisSurvival RateYoung Adult